97 related articles for article (PubMed ID: 29175550)
1. Molecular modeling study on resistance of WT/D473H SMO to antagonists LDE-225 and LEQ-506.
Tu J; Li JJ; Song LT; Zhai HL; Wang J; Zhang XY
Pharmacol Res; 2018 Mar; 129():491-499. PubMed ID: 29175550
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of drug resistance in smoothened receptor: An in silico study of protein resistivity and specificity.
Sinha N; Chowdhury S; Sarkar RR
Proteins; 2020 Mar; 88(3):514-526. PubMed ID: 31589795
[TBL] [Abstract][Full Text] [Related]
3. Biochemical characterization of smoothened receptor antagonists by binding kinetics against drug-resistant mutant.
Shimizu Y; Ishii T; Ogawa K; Sasaki S; Matsui H; Nakayama M
Eur J Pharmacol; 2015 Oct; 764():220-227. PubMed ID: 26048307
[TBL] [Abstract][Full Text] [Related]
4. Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant.
Ishii T; Shimizu Y; Nakashima K; Kondo S; Ogawa K; Sasaki S; Matsui H
Eur J Pharmacol; 2014 Jan; 723():305-13. PubMed ID: 24291104
[TBL] [Abstract][Full Text] [Related]
5. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity.
Zhang H; Sun Z; Liu Z; Song C
Future Med Chem; 2018 Dec; 10(24):2855-2875. PubMed ID: 30557039
[TBL] [Abstract][Full Text] [Related]
6. Analysis of vismodegib resistance in D473G and W535L mutants of SMO receptor and design of novel drug derivatives using molecular dynamics simulations.
Liao S; Floyd C; Verratti N; Leung L; Wu C
Life Sci; 2020 Mar; 244():117302. PubMed ID: 31953165
[TBL] [Abstract][Full Text] [Related]
7. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.
Danial C; Sarin KY; Oro AE; Chang AL
Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616
[TBL] [Abstract][Full Text] [Related]
8. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.
Dijkgraaf GJ; Alicke B; Weinmann L; Januario T; West K; Modrusan Z; Burdick D; Goldsmith R; Robarge K; Sutherlin D; Scales SJ; Gould SE; Yauch RL; de Sauvage FJ
Cancer Res; 2011 Jan; 71(2):435-44. PubMed ID: 21123452
[TBL] [Abstract][Full Text] [Related]
9. Small molecule antagonists in distinct binding modes inhibit drug-resistant mutant of smoothened.
Tao H; Jin Q; Koo DI; Liao X; Englund NP; Wang Y; Ramamurthy A; Schultz PG; Dorsch M; Kelleher J; Wu X
Chem Biol; 2011 Apr; 18(4):432-7. PubMed ID: 21513879
[TBL] [Abstract][Full Text] [Related]
10. Deciphering structural stability and binding mechanisms of potential antagonists with smoothened protein.
Sinha N; Chowdhury S; Sarkar RR
J Biomol Struct Dyn; 2018 Aug; 36(11):2917-2937. PubMed ID: 28849750
[TBL] [Abstract][Full Text] [Related]
11. Molecular modeling study on the dynamical structural features of human smoothened receptor and binding mechanism of antagonist LY2940680 by metadynamics simulation and free energy calculation.
Bai Q; Shen Y; Jin N; Liu H; Yao X
Biochim Biophys Acta; 2014 Jul; 1840(7):2128-38. PubMed ID: 24637074
[TBL] [Abstract][Full Text] [Related]
12. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
Danhof R; Lewis K; Brown M
Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
[TBL] [Abstract][Full Text] [Related]
13. Identification of a potent antagonist of smoothened in hedgehog signaling.
Fan J; Li H; Kuang L; Zhao Z; He W; Liu C; Wang Y; Cheng SY; Chen W
Cell Biosci; 2021 Mar; 11(1):46. PubMed ID: 33653381
[TBL] [Abstract][Full Text] [Related]
14. Molecular Modelling of Berberine Derivatives as Inhibitors of Human Smoothened Receptor and Hedgehog Signalling Pathway Using a Newly Developed Algorithm on Anti-Cancer Drugs.
Kaboli PJ; Bazrafkan M; Ismail P; Ling KH
Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):384-400. PubMed ID: 28969581
[TBL] [Abstract][Full Text] [Related]
15. SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.
Della Corte CM; Bellevicine C; Vicidomini G; Vitagliano D; Malapelle U; Accardo M; Fabozzi A; Fiorelli A; Fasano M; Papaccio F; Martinelli E; Troiani T; Troncone G; Santini M; Bianco R; Ciardiello F; Morgillo F
Clin Cancer Res; 2015 Oct; 21(20):4686-97. PubMed ID: 26124204
[TBL] [Abstract][Full Text] [Related]
16. Identification of Novel Smoothened Ligands Using Structure-Based Docking.
Lacroix C; Fish I; Torosyan H; Parathaman P; Irwin JJ; Shoichet BK; Angers S
PLoS One; 2016; 11(8):e0160365. PubMed ID: 27490099
[TBL] [Abstract][Full Text] [Related]
17. Best Matching Protein Conformations and Docking Programs for a Virtual Screening Campaign Against SMO Receptor.
Amendola G; Di Maio D; La Pietra V; Cosconati S
Mol Inform; 2016 Sep; 35(8-9):340-9. PubMed ID: 27546038
[TBL] [Abstract][Full Text] [Related]
18. MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.
Hoch L; Faure H; Roudaut H; Schoenfelder A; Mann A; Girard N; Bihannic L; Ayrault O; Petricci E; Taddei M; Rognan D; Ruat M
FASEB J; 2015 May; 29(5):1817-29. PubMed ID: 25636740
[TBL] [Abstract][Full Text] [Related]
19. Recovery of taste organs and sensory function after severe loss from Hedgehog/Smoothened inhibition with cancer drug sonidegib.
Kumari A; Ermilov AN; Grachtchouk M; Dlugosz AA; Allen BL; Bradley RM; Mistretta CM
Proc Natl Acad Sci U S A; 2017 Nov; 114(48):E10369-E10378. PubMed ID: 29133390
[TBL] [Abstract][Full Text] [Related]
20. Smoothened is a poor prognosis factor and a potential therapeutic target in glioma.
Tu Y; Niu M; Xie P; Yue C; Liu N; Qi Z; Gao S; Liu H; Shi Q; Yu R; Liu X
Sci Rep; 2017 Feb; 7():42630. PubMed ID: 28195165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
